List of Excipients in Branded Drug ALIMTA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	ALIMTA	pemetrexed disodium	0002-7640	HYDROCHLORIC ACID
Eli Lilly and Company	ALIMTA	pemetrexed disodium	0002-7640	MANNITOL
Eli Lilly and Company	ALIMTA	pemetrexed disodium	0002-7640	SODIUM HYDROXIDE

ALIMTA Excipient Strategy and Commercial Opportunities for Pemetrexed

Last updated: October 13, 2026

ALIMTA is Eli Lilly’s brand of pemetrexed for injection, an intravenous antifolate used primarily in non-small-cell lung cancer and malignant pleural mesothelioma. Its core composition-of-matter and method-of-use exclusivity have largely expired, and generic pemetrexed has materially reduced the commercial value of the original brand. The strongest current opportunities are in sterile excipient supply, lyophilized injectable manufacturing, ready-to-use presentations, hospital procurement, and differentiated delivery systems rather than in broad patent protection for the active ingredient.

ALIMTA’s labeled excipient system is relatively simple: mannitol as the principal bulking agent, with hydrochloric acid and sodium hydroxide used for pH adjustment. That simplicity creates a low barrier for standard generic products but leaves room for suppliers and manufacturers that can improve stability, reconstitution, handling, packaging, or administration economics.

What excipients are used in ALIMTA?

ALIMTA is supplied as a sterile, preservative-free lyophilized powder for intravenous infusion. The principal inactive ingredient is mannitol.

Product characteristic	ALIMTA information
Active ingredient	Pemetrexed disodium
Dosage form	Sterile lyophilized powder for injection
Administration	Intravenous infusion after reconstitution and dilution
Principal excipient	Mannitol
pH-adjusting agents	Hydrochloric acid and sodium hydroxide
Common vial strengths	100 mg and 500 mg pemetrexed equivalent
Diluent	0.9% sodium chloride injection
Preservatives	None
Primary commercial setting	Oncology hospitals and infusion centers

The product is reconstituted with preservative-free 0.9% sodium chloride and then diluted for intravenous infusion. The label also requires folic acid and vitamin B12 supplementation as part of the pemetrexed treatment regimen, but these are clinical co-medications rather than ALIMTA formulation excipients. [1]

Why mannitol is commercially relevant

Mannitol is widely used in lyophilized parenteral products because it can provide cake structure and improve the physical appearance of the freeze-dried product. For pemetrexed, the excipient also supports a relatively straightforward formulation and reconstitution process.

The formulation does not rely on a complex lipid system, polymeric depot, surfactant platform, or proprietary delivery vehicle. That limits formulation complexity but reduces the opportunity to create broad composition-of-matter barriers around the excipient system.

What patents protect ALIMTA and its formulation?

The principal ALIMTA patent estate historically covered pemetrexed chemistry, pharmaceutical compositions, and clinical use. The strongest historical protection was directed to the active pharmaceutical ingredient and therapeutic regimen, not to a highly differentiated excipient platform.

Protection category	Commercial relevance
Pemetrexed composition-of-matter patents	Protected the active molecule and related antifolate compounds
Pemetrexed disodium formulation claims	Covered pharmaceutical compositions and injectable presentations
Combination-use patents	Covered pemetrexed use with folic acid and vitamin B12 supplementation
Manufacturing patents	Potentially covered synthesis, purification, or salt formation
Excipient claims	Limited relative importance because mannitol-based injectable systems are conventional

U.S. Patent No. 5,344,932 was among the principal historical patents associated with pemetrexed and expired in the early 2010s, subject to patent-term adjustments and extensions. Later patents covering the folic acid and vitamin B12 regimen extended protection for certain methods of use beyond the basic compound patent. [2]

The practical result was a staged erosion of exclusivity:

1. The core chemical protection expired first.
2. Generic manufacturers challenged later method-of-use and formulation listings.
3. Settlement agreements controlled the timing of commercial generic entry.
4. Generic pemetrexed products entered after the principal commercial barriers were reduced.

Patent protection for the use of mannitol itself is unlikely to create a meaningful standalone barrier. Mannitol is a conventional excipient with extensive prior use in injectable and lyophilized products. A defensible formulation patent would need to claim a specific technical combination, such as an unusual concentration range, improved stability profile, reduced reconstitution time, lower particulate formation, or a defined container-closure system.

When did ALIMTA lose exclusivity?

ALIMTA lost effective market exclusivity in stages rather than on a single date.

Event	Approximate timing	Effect
Original FDA approval	2004	Established the branded pemetrexed market
Core compound patent expiry	Early 2010s	Removed the principal chemical barrier
Vitamin supplementation method patents	Late 2010s to early 2020s	Delayed certain generic strategies
Generic pemetrexed launches	2022 onward	Created direct price competition
Current market position	Post-generic	Brand retains clinical familiarity but faces procurement pressure

The FDA approved ALIMTA in February 2004 for malignant pleural mesothelioma in combination with cisplatin. It later expanded the product’s use in non-small-cell lung cancer. [3]

Eli Lilly reported substantial ALIMTA revenue before generic competition. The product generated more than $2 billion annually during its peak commercial period, but sales declined as patents expired and generic pemetrexed became available. [4]

What was the impact of generic entry?

Generic entry affects ALIMTA through three channels:

• Lower acquisition prices in hospital tenders.
• Substitution from branded vials to generic pemetrexed.
• Reduced willingness by providers to pay for the original brand without a clinical or operational advantage.

The commercial decline is greater for a hospital-administered injectable than for a chronic oral drug when purchasing systems treat products as therapeutically interchangeable. However, shortages, supplier reliability, vial sizes, reimbursement policy, and oncologist familiarity can preserve limited brand demand.

What is the Orange Book status of ALIMTA?

ALIMTA is an NDA product listed in the FDA Orange Book. Its historical Orange Book listings included patents associated with pemetrexed composition, formulation, and methods of use. The commercial importance of an Orange Book listing depends on whether the patent remains unexpired and whether a generic applicant files a Paragraph IV certification.

The Orange Book does not itself determine whether a formulation has strong commercial exclusivity. It records listed patents and regulatory exclusivity. A formulation patent can be listed but still face invalidity, noninfringement, obviousness, or claim-construction risks in litigation.

For pemetrexed, the most important Orange Book and litigation issues historically involved:

• The active drug and its salt form.
• Use of pemetrexed with folic acid and vitamin B12.
• Generic product labeling and carve-outs.
• The timing of commercial entry under settlement agreements.

A current investment or licensing decision should distinguish expired listings from any remaining unexpired claim that could block a specific product presentation. [5]

Which companies challenged ALIMTA patents?

Multiple generic manufacturers pursued pemetrexed products through the abbreviated new drug application pathway. Public litigation and settlement activity involved companies including Teva and other generic drug manufacturers.

The central litigation pattern was a Paragraph IV challenge. A generic applicant asserted that a listed patent was invalid, unenforceable, or would not be infringed by its proposed product. The patent holder then sued within the statutory window, triggering a regulatory stay and creating a negotiation framework for potential early entry.

What did Paragraph IV challenges mean for pemetrexed?

Paragraph IV litigation did not necessarily produce immediate generic marketing. The commercial result depended on:

• The patents identified in the ANDA certification.
• The claims asserted by the brand company.
• The timing of settlement agreements.
• The scope of any authorized generic arrangement.
• Whether the generic label carved out patented methods of use.

Pemetrexed was commercially important because the product’s method-of-use patents covered the supplementation regimen used in clinical practice. Generic manufacturers had to manage label language carefully to avoid unnecessary infringement exposure while preserving a clinically usable product.

How strong is the ALIMTA patent estate?

The current patent estate is materially weaker than the historical estate because the principal chemical and clinical-use barriers have expired or lost practical blocking power.

Patent estate factor	Assessment
Active ingredient protection	Weak to expired in major markets
Standard mannitol formulation	Weak
Lyophilization process	Moderate only if narrowly claimed and technically demonstrated
Vitamin supplementation method	Historically strong, now largely expired or commercially diminished
Manufacturing process	Potentially relevant to suppliers, but usually avoidable
Device or packaging protection	Opportunity remains for differentiated presentations
Biosimilar protection	Not applicable

The strongest remaining intellectual-property strategy is not a broad claim to "pemetrexed plus mannitol." That subject matter would face substantial prior-art and obviousness risk. More viable claims could cover:

• A defined lyophilized cake with improved reconstitution performance.
• A specified moisture or residual-solvent profile.
• A container-closure system that improves shelf life.
• A ready-to-use pemetrexed solution with demonstrated stability.
• A dual-chamber or closed-system transfer device.
• A manufacturing process that reduces impurities or particulate matter.
• A concentration or vial configuration that reduces drug waste.

These claims would still need a clear technical effect and comparative data against conventional pemetrexed products.

What formulation patents could create new commercial value?

Ready-to-use liquid pemetrexed

A ready-to-use presentation could reduce pharmacy compounding steps, reconstitution errors, and preparation time. The technical challenge is stability. Pemetrexed is supplied commercially as a lyophilized product partly because a liquid presentation must address degradation, pH control, oxidation, adsorption, container compatibility, and long-term sterility.

A viable liquid product could use:

• A controlled pH range.
• An optimized buffer system.
• Low-sorption container materials.
• Nitrogen headspace or oxygen control.
• A terminally sterilized or aseptically filled process.
• A stability-indicating analytical package.

The commercial value would depend on whether hospitals reward workflow savings and lower preparation risk sufficiently to offset manufacturing and cold-chain costs.

Improved lyophilized formulation

A differentiated lyophilized formulation could target:

• Faster reconstitution.
• Reduced foaming.
• Lower residual moisture.
• Improved cake integrity.
• Reduced particulates.
• Longer room-temperature stability.
• More consistent withdrawal from the vial.

This approach is less technically risky than a liquid product because it remains close to the established dosage form. Its commercial limitation is that hospitals may not pay a substantial premium for modest handling improvements when inexpensive generics are available.

Alternative vial sizes

Vial optimization is a practical commercial opportunity. Pemetrexed dosing is based on body-surface area, so oncology pharmacies often combine vial sizes and may experience drug wastage.

Potential products include:

• Lower-dose vials for small or pediatric patients.
• Larger vials for high-dose adult regimens.
• Vial combinations designed to reduce residual drug.
• Ready-to-administer bags for common dose bands.

The regulatory pathway and economics would depend on whether the product remains pharmaceutically equivalent to the reference drug or requires a new drug application or 505(b)(2) pathway.

What manufacturing and excipient barriers exist?

Mannitol supply is generally not a major barrier because pharmaceutical-grade mannitol is available from multiple global suppliers. The more important barriers are sterile manufacturing and quality control.

Manufacturing element	Strategic importance
Sterile-grade mannitol	High for product quality, but generally sourceable
Lyophilization capacity	High; specialized equipment and cycle development are required
Aseptic filling	High; capacity can constrain market entry
Container-closure integrity	High for injectable stability and sterility
Particulate control	High in oncology injectables
Reconstitution performance	Important for hospital workflow
Supply continuity	Commercial differentiator during shortages
Analytical impurity control	Important for regulatory approval and batch release

A manufacturer can usually avoid direct infringement of an active pharmaceutical ingredient process patent by using a different synthesis route, subject to regulatory and freedom-to-operate analysis. Excipient sourcing creates fewer patent risks than the synthesis of pemetrexed, but supplier qualification and change-control requirements can make substitution operationally difficult.

Does ALIMTA have biosimilar risk?

No. ALIMTA is a small-molecule drug, not a biologic. It is not subject to biosimilar competition under the FDA’s Biologics Price Competition and Innovation Act pathway.

The relevant competitors are:

• ANDA-approved generic pemetrexed injections.
• Authorized generic products.
• Alternative pemetrexed salts or presentations where approved.
• Hospital-compounded or pharmacy-prepared products in limited circumstances.
• Other lung-cancer regimens that compete for treatment share.

The absence of biosimilar risk does not eliminate competitive pressure. Generic injectable competition can produce rapid price erosion, particularly when several suppliers qualify for hospital contracts.

What are the commercial opportunities for ALIMTA excipient suppliers?

The largest opportunities are upstream and operational rather than brand-protection opportunities.

Pharmaceutical-grade mannitol

Mannitol suppliers can compete on:

• Parenteral-grade quality.
• Consistent particle-size distribution.
• Low endotoxin and bioburden levels.
• Trace-metal control.
• Reliable global supply.
• Documentation for change management.
• Support for lyophilization cycle development.

Because mannitol is not unique to pemetrexed, demand is tied to the broader injectable and lyophilized-drug market rather than ALIMTA alone.

Custom formulation development

Contract development and manufacturing organizations can create value by offering:

• Lyophilization cycle optimization.
• Generic formulation development.
• Liquid stability programs.
• Container-closure selection.
• Extractables and leachables testing.
• Sterility and particulate-control systems.
• Scale-up and process validation.

Closed-system transfer and administration

A closed-system transfer device can reduce occupational exposure during oncology drug preparation. The commercial opportunity is strongest where a product can combine pemetrexed supply with an integrated transfer or administration system.

The value proposition is operational rather than therapeutic:

• Fewer compounding steps.
• Lower handling risk.
• Reduced drug waste.
• Improved workflow standardization.
• Potentially lower preparation labor.

The device may be protected separately through mechanical, packaging, or system patents even when the pemetrexed formulation itself is no longer strongly protected.

How does ALIMTA compare with competing oncology injectables?

Attribute	ALIMTA/pemetrexed	Conventional generic oncology injectables	Biologic oncology drugs
Molecular type	Small molecule	Small molecule	Biologic
Regulatory route	NDA/ANDA	ANDA	BLA/biosimilar
Biosimilar exposure	None	None	High where patents permit
Formulation complexity	Moderate	Low to moderate	Often high
Main dosage form	Lyophilized powder	Powder or liquid	Liquid, frozen, or lyophilized
Excipient differentiation	Limited but possible	Variable	Often central to stability
Main commercial barrier	Clinical familiarity and supply	Cost and tender access	Manufacturing, patents, interchangeability
Best IP opportunity	Formulation, device, process	Process and presentation	Molecule, formulation, device, use

Compared with biologic oncology drugs, ALIMTA has a simpler excipient strategy and lower formulation IP value. Compared with conventional generic injectables, it has a more established clinical role and a higher-value oncology supply chain, which can support premium offerings tied to reliability and workflow.

What generic launch scenarios exist for pemetrexed?

Low-price commodity launch

Multiple generic manufacturers compete primarily on price. The product is supplied in standard lyophilized vials with conventional reconstitution instructions. Margins decline as hospital purchasing groups consolidate volume.

Supply-reliability launch

A manufacturer differentiates through consistent supply, dual-source excipients, regional manufacturing, and shortage mitigation. This strategy can preserve contracts even without formulation exclusivity.

Workflow-improvement launch

A company introduces a ready-to-use liquid, optimized vial configuration, or integrated transfer system. The product seeks a premium based on reduced pharmacy labor and lower preparation risk.

Specialty-distribution launch

A manufacturer focuses on selected oncology networks, integrated delivery systems, or regional hospital groups. The strategy emphasizes service levels and inventory management rather than national price leadership.

What is the litigation and settlement outlook?

The principal ALIMTA patent disputes were tied to generic entry and method-of-use rights. As the major patents expire, new litigation is more likely to involve:

• Formulation patents for liquid or concentrated products.
• Manufacturing-process patents.
• Device and administration systems.
• Trade secrets involving impurity control or lyophilization cycles.
• ANDA patent certifications for newly listed patents.

Settlement agreements can still affect launch timing where a generic applicant challenges a later-expiring formulation or use patent. A settlement may permit entry before patent expiry, impose label restrictions, or include commercial terms such as authorized supply arrangements. The commercial significance of any settlement depends on the number of potential entrants and whether the agreement delays all competitors or only one applicant.

What geographic opportunities exist for pemetrexed products?

The United States remains important because of the size of the oncology market and structured ANDA litigation. Europe and other regulated markets offer opportunities for generic pemetrexed, but pricing pressure is often stronger because of centralized procurement and reference pricing.

Region	Opportunity profile
United States	ANDA competition, hospital contracts, formulation differentiation
European Union	Generic substitution, tender access, centralized procurement
Japan	Regulatory and local market-access requirements
China	High-volume oncology demand, local manufacturing competition
Emerging markets	Price-sensitive demand, injectable supply gaps, local registration

A formulation or device patent should be filed selectively. Broad international filing is less attractive for a standard mannitol-based product unless the innovation has demonstrated commercial value and a credible enforcement pathway.

Key Takeaways

• ALIMTA is a lyophilized pemetrexed injection whose principal excipient is mannitol.
• The original product has a relatively simple excipient system and limited room for broad excipient-based exclusivity.
• Core chemical and major method-of-use protections have expired or lost most of their blocking value.
• Generic pemetrexed is the main competitive threat; biosimilars are not relevant.
• The strongest new commercial opportunities are ready-to-use liquids, improved lyophilized cakes, optimized vial sizes, closed-system transfer devices, and supply reliability.
• A patent claiming only pemetrexed and mannitol would likely be weak. Stronger protection would require a defined formulation, measurable technical benefit, or integrated device system.
• Excipient suppliers can capture value through pharmaceutical-grade mannitol, lyophilization support, sterile manufacturing, container-closure systems, and supply-chain resilience.
• Hospital workflow and procurement economics are more important than brand heritage in the post-generic market.

FAQs

Is mannitol in every generic pemetrexed product?

Many generic pemetrexed products use a mannitol-based formulation because it is consistent with the reference product and established injectable development practice. The exact excipient composition must be confirmed from each product’s FDA-approved labeling.

Can a company patent a new pemetrexed excipient formulation?

Yes. A patent may be available for a new formulation if it is novel, nonobvious, adequately disclosed, and supported by a technical effect such as improved stability, reconstitution, or storage performance. Conventional pemetrexed-mannitol combinations face a higher patentability risk.

Is a ready-to-use pemetrexed liquid commercially attractive?

It can be attractive if it demonstrates meaningful shelf life, acceptable packaging, low particulate formation, and lower pharmacy preparation cost. The product must overcome the stability and sterile-manufacturing challenges associated with replacing a lyophilized dosage form.

Does ALIMTA still justify a brand premium?

A premium may persist for supply assurance, clinical familiarity, or contracting reasons, but generic entry has materially weakened the justification for a broad price premium. A durable premium would require a measurable operational or clinical advantage.

What is the best IP strategy for a new pemetrexed product?

The strongest strategy is usually a layered portfolio covering formulation performance, manufacturing controls, container closure, vial configuration, and administration devices. A single broad excipient claim is less defensible than a coordinated portfolio tied to validated product advantages.

References

1. U.S. Food and Drug Administration. (2024). ALIMTA (pemetrexed for injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
2. U.S. Patent and Trademark Office. (1994). U.S. Patent No. 5,344,932, Antifolates. https://patents.google.com/patent/US5344932
3. U.S. Food and Drug Administration. (2004). FDA approves ALIMTA for malignant pleural mesothelioma. https://www.fda.gov/
4. Eli Lilly and Company. (2021). 2021 annual report. https://investor.lilly.com/financial-information/annual-reports
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.